Filtered By:
Condition: Thrombosis
Procedure: Transplants

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 252 results found since Jan 2013.

Bleeding in critical care associated with left ventricular assist devices: pathophysiology, symptoms, and management.
Authors: Leebeek FWG, Muslem R Abstract Chronic heart failure (HF) is a growing health problem, and it is associated with high morbidity and mortality. Left ventricular assist devices (LVADs) are nowadays an important treatment option for patients with end-stage HF not only as a bridging tool to heart transplantation but also, as a permanent therapy for end-stage HF (destination therapy). The use of LVAD is associated with a high risk for bleeding complications and thromboembolic events, including pump thrombosis and ischemic stroke. Bleeding is the most frequent complication, occurring in 30% to 60% of patients, b...
Source: Hematology ASH Education Program - December 7, 2019 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Permanent Implantable Cardiac Support Systems.
CONCLUSION: A VAD system can be implanted as an alternative to cardiac transplan- tation or as a bridging treatment until the patient can be listed for transplantation and receive the transplant. Because of the organ s , only a minority of VAD patients ever receive a transplant. PMID: 31931951 [PubMed - in process]
Source: Deutsches Arzteblatt International - January 16, 2020 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research

Left Ventricular Assist Systems and Strokes- Statins to the Rescue?
The development of durable left ventricular assist systems (LVAS) has been critical in providing an option for management of end-stage heart disease and addressing the increasing gap between demand and supply of donor cardiac allografts for management of end-stage heart disease. The technology also provides an alternative to heart transplantation in many patients. Unfortunately, the long-term use of LVAS has been associated with significant morbidities, the most devastating of which may relate to the thrombogenicity of the artificial devices, leading to ischemic stroke or pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - March 16, 2020 Category: Transplant Surgery Authors: Jignesh Patel Tags: Editorial Source Type: research

Pre-Operative Intracardiac Thrombus is Associated with Increased Risk of Stroke and Death in CF-LVAD Patients
Advanced heart failure predisposes patients to intracardiac thrombus (ICT) formation. There is a paucity of evidence examining the impact of pre-existing left atrial (LA) or left ventricular (LV) thrombi on post-operative outcomes in patients undergoing durable LVAD implantation.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: C.A. Bravo Carillo, J.A. Fried, G.M. Mondellini, A. Javaid, H.S. Lumish, J.Z. Willey, V.K. Topkara, L. Braghieri, Y. Kaku, L. Witer, H. Takayama, K. Takeda, Y. Naka, N. Uriel, M. Yuzefpolskaya, P.C. Colombo Tags: (349) Source Type: research

Inflow Cannula Position as Predictor for Neurological Dysfunction in Patients with HeartMate 3 Left Ventricular Assist Device
This study aimed to investigate pump position, derived from chest X-rays of HM3 patients, in correlation to any neurological dysfunction (ND) and specifically to ischemic stroke (IS) and intracranial hemorrhage (ICH).
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: T. Schl öglhofer, P. Aigner, M. Migas, D. Beitzke, F. Wittmann, J. Riebandt, D. Wiedemann, G. Laufer, F. Moscato, H. Schima, D. Zimpfer Tags: (216) Source Type: research

Natural Antibodies and Left Ventricular Assist Device Complications
Left ventricular assist devices (LVAD) are widely used as a support strategy for advanced heart failure. Complications such as thrombosis and bleeding have been linked to LVAD. We observed that LVAD implantation was followed by a sharp increase in serum levels of IgG natural antibodies (Nabs) recognizing oxidation-specific epitopes (OSE) and apoptotic cells. Nabs have been implicated in inflammatory reactions related to atherosclerosis, ischemic stroke and primary graft dysfunction following heart transplantation.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: S.B. See, D. Onat, E. Hittesdorf, F. McDougan, M. Yuzefpolskaya, A.R. Garan, V.K. Topkara, Y. Naka, H. Takayama, K. Takeda, G.P. Milligan, D. Wencker, S.A. Hall, M. Askar, P. Kimball, G. Wagener, P. Colombo, E. Zorn Tags: (1211) Source Type: research

Left ventricular assist systems and strokes: Statins to the rescue?
The development of durable left ventricular assist systems (LVASs) has been critical in providing an option for management of end-stage heart disease and addressing the increasing gap between demand and supply of donor cardiac allografts for management of end-stage heart disease. The technology also provides an alternative to heart transplantation in many patients. Unfortunately, the long-term use of LVASs has been associated with significant morbidities, the most devastating of which may relate to the thrombogenicity of the artificial devices, leading to ischemic stroke or pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - March 16, 2020 Category: Transplant Surgery Authors: Jignesh K. Patel Tags: EDITORIAL COMMENTARY Source Type: research

Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)
After solid organ or hematopoietic stem cell transplantation (HSCT), the risk of arterial or venous thromboembolism (VTE) is high (1 –7). Oral anticoagulation represents the mainstay for stroke prevention in atrial fibrillation (SPAF) and VTE treatment. The pharmacodynamic and pharmacokinetic profiles of vitamin k antagonists (VKA) represent a challenge especially in the setting of transplantation, also due to the high risk of bleeding (8) and due to complex co-medications of transplant recipients.
Source: Thrombosis Research - April 23, 2020 Category: Hematology Authors: Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Luise Tittl, Katja Sockel, Jan Moritz Middecke, Martin Bornh äuser Tags: Letter to the Editors-in-Chief Source Type: research

High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.
CONCLUSIONS: We found elevated plasma levels of cleaved HK in sickle patients compared to healthy controls, suggesting ongoing HK activation in SCD. We used bone marrow transplantation to generate wild type and sickle cell mice on a HK-deficient background. We found that short-term HK deficiency attenuated thrombin generation and inflammation in sickle mice at steady state, which was independent of bradykinin signaling. Moreover, long-term HK deficiency attenuates kidney injury, reduces chronic inflammation, and ultimately improves of sickle mice. PMID: 32573897 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 22, 2020 Category: Hematology Authors: Sparkenbaugh EM, Kasztan M, Henderson MW, Ellsworth P, Davis PR, Wilson KJ, Reeves B, Key NS, Strickland S, McCrae K, Pollock DM, Pawlinski R Tags: J Thromb Haemost Source Type: research

Biventricular imaging markers to predict outcomes in non ‐compaction cardiomyopathy: a machine learning study
ConclusionsOur findings show the importance of biventricular assessment to detect the severity of this cardiomyopathy and to plan for early clinical intervention. In addition, this study shows that even patients with normal LV function and negative late gadolinium enhancement had MACE. ML is a promising tool for analysing a large set of parameters to stratify and predict prognosis in LVNC patients.
Source: ESC Heart Failure - June 29, 2020 Category: Cardiology Authors: Camila Rocon, Mahdi Tabassian, Marcelo Dantas Tavares de Melo, Jose Arimateia Araujo Filho, Cesar Jos é Grupi, Jose Rodrigues Parga Filho, Edimar Alcides Bocchi, Jan D'hooge, Vera Maria Cury Salemi Tags: Original Research Article Source Type: research

A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible Blood Propulsion.
P, Potapov E, Falk V, Mazza E Abstract Heart failure is a raising cause of mortality. Heart transplantation and ventricular assist device (VAD) support represent the only available lifelines for end stage disease. In the context of donor organ shortage, the future role of VAD as destination therapy is emerging. Yet, major drawbacks are connected to the long-term implantation of current devices. Poor VAD hemocompatibility exposes the patient to life-threatening events, including haemorrhagic syndromes and thrombosis. Here, we introduce a new concept of artificial support, the Hybrid Membrane VAD, as a first-of-its...
Source: Annals of Biomedical Engineering - September 7, 2020 Category: Biomedical Engineering Authors: Ferrari A, Giampietro C, Bachmann B, Bernardi L, Bezuidenhhout D, Ermanni P, Hopf R, Kitz S, Kress G, Loosli C, Marina V, Meboldt M, Pellegrini G, Poulikakos D, Rebholz M, Schmid Daners M, Schmidt T, Starck C, Stefopoulos G, Sündermann S, Thamsen B, Zill Tags: Ann Biomed Eng Source Type: research

Identification of characteristics, risk factors, and predictors of recurrent LVAD thrombosis: conditions in HeartWare devices
ConclusionRecurrent HVAD thrombosis mostly appears within 12  months after first thrombosis. Systemic t-PA therapy for recurrent pump thrombosis seems safe, achieving comparable effectiveness rates to initial t-PA therapy. Survival does not differ between patients with or without recurrent HVAD thrombosis.
Source: Journal of Artificial Organs - December 18, 2020 Category: Transplant Surgery Source Type: research

Management of Intracranial Hemorrhage in Patients with a Left Ventricular Assist Device: A Systematic Review and Meta-Analysis
Left Ventricular Assist Device (LVAD) therapy serves as a surgically implanted form of mechanical circulation in patients with advanced heart failure. Initially designed to provide a bridge to transplant, LVADs now offer an alternative that is increasingly utilized as final destination therapy as the need for donor hearts increases worldwide.1,2 However, this requires lifelong anticoagulation (AC) to prevent pump thrombosis, resulting in hemorrhagic risks.3
Source: Journal of Stroke and Cerebrovascular Diseases - December 1, 2020 Category: Neurology Authors: Austin H. Carroll, Michael P. Ramirez, Ehsan Dowlati, Kyle B. Mueller, Ali Borazjani, Jason J. Chang, Daniel R. Felbaum Tags: Review Article Source Type: research

Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation
ConclusionsLeft ventricular assist device therapy can impair the outcome after HTx. However, the occurrence of LVAD complications may not impact on outcome after HTx. Thus, we cannot support the prioritization or discrimination of HTx candidates according to distinct mechanical circulatory support ‐associated complications. Future allocation strategies have to respect that device‐related complications may define urgency but do not impact on the outcome after HTx.
Source: ESC Heart Failure - January 21, 2021 Category: Cardiology Authors: Moritz Benjamin Immohr, Udo Boeken, Franziska Mueller, Emir Prashovikj, Michiel Morshuis, Charlotte B öttger, Hug Aubin, Jan Gummert, Payam Akhyari, Artur Lichtenberg, René Schramm Tags: Original Research Article Source Type: research

Systemic tPA Treatment for Thrombosis in a Patient with Dilated Cardiomyopathy on Berlin Heart
We present a case of thrombosis in a patient on Berlin Heart LVAD that was successfully treated with systemic alteplase.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: L.D. Glass, R. Murthy, P. Pastuszko Tags: (1357) Source Type: research